Rein Therapeutics

Rein Therapeutics is a biopharmaceutical company specializing in stapled peptide technology, focused on transforming the chemotherapy experience for cancer patients by enabling them to fight cancer without fearing the side effects or burden caused by chemotherapy. ALRN-6924, our first-in-class dual MDM2/MDMX inhibitor currently under clinical development, aims to provide a single-agent solution that protects various healthy cells throughout the body from chemotherapy while ensuring that chemotherapy continues to destroy cancer cells.